{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:15:42Z","timestamp":1790878542034,"version":"4.1.0"},"reference-count":35,"publisher":"American Chemical Society (ACS)","issue":"7","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372014"],"award-info":[{"award-number":["82372014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Physician-Scientist Development Award from Shanghai Immune Therapy Institute","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Precise diagnosis of primary and metastatic clear cell renal cell carcinoma (ccRCC) is an unmet clinical challenge. CD70 is a biomarker for ccRCC, with high, consistent expression in both primary and metastatic diseases. Devising immuno-positron emission tomography\/computed tomography (immunoPET\/CT) imaging tracers targeting CD70 will enable noninvasive, accurate diagnosis of ccRCC. By immunizing alpacas with the recombinant human CD70 protein, we obtained a single-domain antibody (sdAb), R8B4, with an affinity of 9.583 nM. First, by harnessing 18F labeling, we developed a CD70 immunoPET\/CT tracer, [18F]AlF-RESCA-R8B4, and verified its diagnostic accuracy in preclinical ccRCC models. Subsequently, the more readily available [68Ga]Ga-NOTA-R8B4 was constructed using 68Ga labeling, and its targeting performance was also validated. Compared with [18F]AlF-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4 showed lower renal accumulation. Following this, we conducted a preliminary investigator-initiated clinical trial that demonstrated that [18F]AlF-RESCA-R8B4 clearly visualized CD70-positive metastatic lesions in ccRCC patients. With improved pharmacokinetics and reduced kidney accumulation, [68Ga]Ga-NOTA-R8B4 immunoPET\/CT shows preliminary, yet promising, value for accurately detecting primary lesions in ccRCC patients. Future studies are warranted to explore the diagnostic and predictive value of the CD70-targeted immunoPET\/CT imaging approaches in ccRCC patients.<\/jats:p>","DOI":"10.1021\/cbmi.6c00002","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T05:41:48Z","timestamp":1771566108000},"page":"1521-1529","source":"Crossref","is-referenced-by-count":2,"title":["[18F]AlF-RESCA-R8B4\nand [68Ga]Ga-NOTA-R8B4:\nA Pair of Novel CD70-Targeted ImmunoPET\/CT Imaging Agents for Clinical\nUse"],"prefix":"10.1021","volume":"4","author":[{"given":"You","family":"Zhang","sequence":"first","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyun","family":"Wu","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxian","family":"An","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Xu","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Jia","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhoumi","family":"Hu","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Huang","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Liu","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-2480","authenticated-orcid":true,"given":"Weijun","family":"Wei","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University , , 1630 Dongfang Rd , ,","place":["Shanghai, China, 200127"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"issue":"10451","key":"2026073100224906200_cit1","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"2026073100224906200_cit2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s41585-024-00962-z","article-title":"Molecular imaging of renal cell carcinomas:\nready for prime time","volume":"22","author":"Wu","year":"2025","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"2026073100224906200_cit3","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association\nof Urology Guidelines on Renal Cell Carcinoma: The 2022 Update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur. Urol."},{"issue":"25","key":"2026073100224906200_cit4","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management\nof Metastatic\nClear Cell Renal Cell Carcinoma: ASCO Guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"2026073100224906200_cit5","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41585-024-00876-w","article-title":"Von Hippel-Lindau protein signalling in clear cell\nrenal cell carcinoma","volume":"21","author":"Liao","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"2026073100224906200_cit6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1053\/j.semnuclmed.2025.08.001","article-title":"CD70-Targeted\nRadiotheranostics:\nNow and Future","volume":"55","author":"Shi","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"8","key":"2026073100224906200_cit7","doi-asserted-by":"publisher","first-page":"100671","DOI":"10.1016\/j.medj.2025.100671","article-title":"CD70-targeted\ncancer theranostics:\nProgress and challenges","volume":"6","author":"Wei","year":"2025","journal-title":"Med."},{"issue":"7","key":"2026073100224906200_cit8","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70400","article-title":"CD70: An emerging\ntarget for integrated cancer diagnosis and therapy","volume":"15","author":"Hu","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"2026073100224906200_cit9","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2025.11.007","article-title":"New targets of PET imaging for renal\ncancer","author":"Katayeu","year":"2025","journal-title":"Semin. Nucl. Med."},{"issue":"1","key":"2026073100224906200_cit10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-med-070623-045906","article-title":"CD70: An\nEmerging Anticancer Target\nin Renal Cell Carcinoma and Beyond","volume":"76","author":"Zang","year":"2025","journal-title":"Annu. Rev.\nMed."},{"issue":"5","key":"2026073100224906200_cit11","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2967\/jnumed.123.266309","article-title":"Preclinical Characterization of DPI-4452: A68Ga\/177Lu\nTheranostic Ligand for Carbonic Anhydrase IX","volume":"65","author":"Massie\u0300re","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026073100224906200_cit12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.2967\/jnumed.123.267175","article-title":"First-in-Human Safety, Imaging, and\nDosimetry of a Carbonic Anhydrase IX\u2013Targeting Peptide, [68Ga]Ga-DPI-4452,\nin Patients with Clear Cell Renal Cell Carcinoma","volume":"65","author":"Hofman","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026073100224906200_cit13","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1021\/acs.chemrev.9b00738","article-title":"ImmunoPET: Concept, Design, and Applications","volume":"120","author":"Wei","year":"2020","journal-title":"Chem. Rev."},{"issue":"10","key":"2026073100224906200_cit14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","article-title":"[89Zr]Zr-girentuximab\nfor PET\u2013CT imaging of\nclear-cell renal cell carcinoma: a prospective, open-label, multicentre,\nphase 3 trial","volume":"25","author":"Shuch","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026073100224906200_cit15","doi-asserted-by":"publisher","first-page":"885","DOI":"10.2967\/jnumed.117.199901","article-title":"Same-Day Imaging\nUsing Small Proteins: Clinical Experience and Translational Prospects\nin Oncology","volume":"59","author":"Krasniqi","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026073100224906200_cit16","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.2967\/jnumed.122.263907","article-title":"Single-Domain\nAntibody Theranostics on the Horizon","volume":"63","author":"Wei","year":"2022","journal-title":"J. Nucl.\nMed."},{"issue":"5","key":"2026073100224906200_cit17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/s44321-024-00059-5","article-title":"ImmunoPET imaging of Trop2 in patients with solid tumours","volume":"16","author":"Huang","year":"2024","journal-title":"EMBO Mol. Med."},{"issue":"1","key":"2026073100224906200_cit18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","article-title":"Phase\nI Study of 68Ga-HER2-Nanobody for PET\/CT Assessment\nof HER2 Expression in Breast Carcinoma","volume":"57","author":"Keyaerts","year":"2016","journal-title":"J. Nucl.\nMed."},{"issue":"8","key":"2026073100224906200_cit19","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1007\/s00259-024-06672-3","article-title":"ImmunoPET\/CT imaging of clear cell\nrenal cell carcinoma with [(18)F]RCCB6: a first-in-human study","volume":"51","author":"Wu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"12","key":"2026073100224906200_cit20","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.2967\/jnumed.124.268509","article-title":"CD70-Targeted\nImmuno-PET\/CT Imaging of Clear Cell Renal Cell Carcinoma:\nA Translational Study","volume":"65","author":"Zhou","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026073100224906200_cit21","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00259-024-07001-4","article-title":"[(18)F]RCCB6 immunoPET\/CT\ndetects primary clear cell renal cell carcinoma","volume":"52","author":"Wu","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026073100224906200_cit22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.eururo.2024.06.020","article-title":"[(18)F]RCCB6 Immuno-Positron\nEmission Tomography\/Computed Tomography for Postoperative Surveillance\nin Clear Cell Renal Cell Carcinoma: A Pilot Clinical Study","volume":"86","author":"Wu","year":"2024","journal-title":"Eur. Urol."},{"key":"2026073100224906200_cit23","doi-asserted-by":"publisher","first-page":"270958","DOI":"10.2967\/jnumed.125.270958","article-title":"CD70-Targeted\n[(18)F]RCCB6 Immuno-PET\/CT for Diagnosing Clear Cell Renal Cell Carcinoma\nMetastases: A Prospective Study","volume":"125","author":"Ma","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"7","key":"2026073100224906200_cit24","doi-asserted-by":"publisher","first-page":"12913","DOI":"10.3390\/molecules200712913","article-title":"68Ga-Based\nradiopharmaceuticals: production and application relationship","volume":"20","author":"Velikyan","year":"2015","journal-title":"Molecules"},{"issue":"10","key":"2026073100224906200_cit25","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/s41596-018-0040-7","article-title":"Direct fluorine-18\nlabeling of heat-sensitive\nbiomolecules for positron emission tomography imaging using the Al(18)F-RESCA\nmethod","volume":"13","author":"Cleeren","year":"2018","journal-title":"Nat. Protoc."},{"issue":"11","key":"2026073100224906200_cit26","doi-asserted-by":"publisher","first-page":"e902","DOI":"10.1016\/S2352-3026(23)00207-7","article-title":"Cusatuzumab plus azacitidine in newly diagnosed\nacute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE):\npart one of a randomised, phase 2, dose optimization study","volume":"10","author":"Pabst","year":"2023","journal-title":"Lancet Haematol."},{"issue":"5","key":"2026073100224906200_cit27","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/cncr.34005","article-title":"Cusatuzumab for treatment of CD70-positive\nrelapsed or refractory cutaneous T-cell lymphoma","volume":"128","author":"Leupin","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"2026073100224906200_cit28","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1111\/cts.13089","article-title":"An open-label, nonrandomized,\nphase Ib feasibility study of cusatuzumab in patients with nasopharyngeal\ncarcinoma","volume":"14","author":"De Meulenaere","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"2026073100224906200_cit29","doi-asserted-by":"publisher","first-page":"105067","DOI":"10.1016\/j.critrevonc.2025.105067","article-title":"Antibody-Drug\nConjugates in urothelial, prostate, and renal cell cancers: A review\nof current and emerging therapies","volume":"218","author":"Perera","year":"2026","journal-title":"Crit Rev.\nOncol Hematol"},{"issue":"7","key":"2026073100224906200_cit30","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-Targeted\nAllogeneic CAR T-Cell Therapy\nfor Advanced Clear Cell Renal Cell Carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"},{"issue":"3","key":"2026073100224906200_cit31","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S1470-2045(19)30821-6","article-title":"Radiotheranostics:\na roadmap for future development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"2026073100224906200_cit32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy\nof human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"2026073100224906200_cit33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-008794","article-title":"Preclinical development\nof novel PD-L1 tracers and first-in-human\nstudy of [(68)Ga]Ga-NOTA-RW102 in patients with lung cancers","volume":"12","author":"Zhang","year":"2024","journal-title":"J. Immunother Cancer"},{"issue":"9","key":"2026073100224906200_cit34","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00259-021-05218-1","article-title":"ImmunoPET imaging of multiple myeloma with\n[(68)Ga]Ga-NOTA-Nb1053","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"issue":"2","key":"2026073100224906200_cit35","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s00259-024-06910-8","article-title":"ImmunoPET\nimaging of EpCAM in solid tumours with nanobody tracers: a preclinical\nstudy","volume":"52","author":"Xu","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Chemical &amp; Biomedical\nImaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/cbmi.6c00002","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/cbihbp\/article-pdf\/4\/7\/1521\/66282168\/cbmi.6c00002.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/cbihbp\/article-pdf\/4\/7\/1521\/66282168\/cbmi.6c00002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:22:53Z","timestamp":1785471773000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/cbihbp\/article\/4\/7\/1521\/5234111\/18F-AlF-RESCA-R8B4-and-68Ga-Ga-NOTA-R8B4-A-Pair-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":35,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,2,20]]},"published-print":{"date-parts":[[2026,7,27]]}},"URL":"https:\/\/doi.org\/10.1021\/cbmi.6c00002","relation":{},"ISSN":["2832-3637"],"issn-type":[{"value":"2832-3637","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]}}}